Filana Therapeutics, Inc. (FLNA)

Market Cap	48.07M -57.5%
Revenue (ttm)	n/a
Net Income	-42.28M
EPS	-0.88
Shares Out	48.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	614,765
Open	0.9618
Previous Close	0.9590
Day's Range	0.9320 - 1.0250
52-Week Range	0.8564 - 4.9800
Beta	-0.69
Analysts	Buy
Price Target	6.50 (+553.27%)
Earnings Date	Jul 29, 2026

About FLNA

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer’s disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 20
• Stock Exchange: NASDAQ
• Ticker Symbol: FLNA
• Website: https://www.filanatx.com

Analyst Summary

According to 2 analysts, the average rating for FLNA stock is "Buy." The 12-month stock price target is $6.5, which is an increase of 553.27% from the latest price.

Price Target

$6.5

(553.27% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 10, 2026

Data Sources Report a data error